Hemophilia is an inherited bleeding disorder caused by deficiencies in clotting factor VIII, in the case of hemophilia A, or factor IX, in the case of hemophilia B. Because these proteins are essential for forming stable blood clots, affected individuals bleed for longer than normal after injury and can bleed spontaneously into joints, muscles, and, most dangerously, the brain. The disorder is passed on through the X chromosome, so it overwhelmingly affects boys, while girls are typically carriers. What makes the neonatal period so treacherous is the combination of an immature coagulation system, the mechanical stresses of labor and delivery, and the fact that many affected infants are born into families with no known history of the disease. In roughly a third of cases, hemophilia appears in a child with no prior family history, arising from a new genetic mutation, which means neither obstetricians nor parents may anticipate the bleeding risk before delivery.

Intracranial hemorrhage in a newborn is a medical emergency of the highest order. Bleeding can occur in several compartments of the skull: inside the brain tissue itself, in the subdural space beneath the dura mater, in the subarachnoid space surrounding the brain, or within the ventricles, the fluid-filled cavities deep in the brain. In a baby with hemophilia, even a minor trauma during delivery, such as the pressure of forceps, a vacuum extraction, or a prolonged second stage of labor, can trigger bleeding that a healthy infant’s clotting system would quickly contain. Symptoms may include seizures, lethargy, vomiting, a bulging fontanelle, pallor, or simply poor feeding and irritability, and because these signs overlap with many other neonatal conditions, diagnosis is often delayed. Untreated, the bleed can expand, compressing brain tissue and causing permanent damage or death.

The true scale of the problem has long been difficult to pin down. Previous estimates of neonatal ICH risk in hemophilia have ranged widely across the literature, from figures below one percent to reports suggesting rates several times higher. The authors of the new analysis attribute this fragmentation to heterogeneous study designs, small single-center cohorts, differing diagnostic criteria, and inconsistent surveillance practices. Some studies relied on clinical symptoms alone, others on routine cranial imaging, and the era in which each study was conducted matters as well, since the availability of neonatal ultrasound, computed tomography, and magnetic resonance imaging has changed dramatically over recent decades. By systematically searching PubMed, Embase, and Scopus from their inception through November 2025 and applying consistent eligibility criteria, requiring reported ICH within the first twenty-eight days of life among live-born neonates with hemophilia, the team sought to produce the most reliable estimate to date.

The statistical machinery behind the study is standard for modern evidence synthesis but worth unpacking. Rather than simply averaging the results of the thirteen included studies, the researchers used a random-effects meta-analysis, a model that assumes each study estimates its own true incidence and that these true values are distributed around a common mean. This approach is appropriate when between-study heterogeneity is high, which the authors confirmed it was. Heterogeneity in this context means the studies differed substantially in their reported rates, likely reflecting differences in geography, era, severity of hemophilia represented, mode of delivery, and intensity of diagnostic workup. The random-effects model widens the confidence interval to account for this variability, which is why the pooled estimate of 2.10 percent carries an interval stretching from 1.40 to 2.79 percent rather than a razor-thin range.

One of the more sobering findings concerns mortality. The pooled estimate for fatal neonatal ICH was approximately 0.2 percent, with a 95 percent confidence interval of 0.0 to 1.2 percent. In other words, among every thousand live-born neonates with hemophilia, roughly two may die from a brain bleed in the first month of life, though the wide interval reflects the rarity of the event and the limits of the available data. Fatal bleeds were rare in absolute terms, but the analysis underscores that when ICH does occur, it carries the potential for catastrophic outcomes. Survivors of neonatal ICH can face cerebral palsy, epilepsy, developmental delay, and cognitive impairment, making prevention far more valuable than even the best acute treatment.

Prevention, the authors argue, hinges on three pillars: early diagnosis, careful perinatal management, and avoidance of traumatic delivery techniques. Early diagnosis means identifying at-risk infants before or immediately after birth, ideally through known family history, carrier testing, or, in some health systems, targeted newborn screening of male infants born to carrier mothers. Careful perinatal management involves coordinating obstetric and hematology teams well before delivery, planning the mode of birth to minimize trauma, and avoiding invasive monitoring such as fetal scalp electrodes or vacuum and rotational forceps deliveries when a baby is known or suspected to have hemophilia. For infants diagnosed after birth, prompt replacement of the missing clotting factor can halt bleeding before it spreads, and some guidelines recommend prophylactic factor replacement for high-risk neonates during the vulnerable first days of life.

The study’s findings arrive amid a broader shift in hemophilia care. Prophylactic clotting factor infusions, once reserved for older children with severe disease, are increasingly considered earlier, and newer agents, including extended half-life factor products and bispecific antibodies that mimic factor VIII activity, have transformed long-term management. Yet the neonatal window remains a blind spot in many treatment pathways, because diagnosis itself may lag behind the highest-risk period. The authors call for dedicated neonatal-focused registries and prospective studies to refine risk stratification, arguing that only systematically collected, individual-level data can identify which babies are most likely to bleed and which preventive strategies work best. Such registries could track delivery mode, factor levels at birth, family history, imaging findings, and outcomes in a standardized way across centers and countries.

The meta-analysis also highlights persistent gaps in the evidence base. The thirteen included studies spanned different decades, healthcare settings, and diagnostic standards, and the authors note that the substantial heterogeneity between them limits the precision of any single pooled estimate. Retrospective designs dominated, and few studies distinguished between severity categories of hemophilia, modes of delivery, or the timing and type of diagnostic imaging. Without prospective, standardized surveillance, some bleeds may go undetected, particularly small hemorrhages that produce subtle or absent symptoms in the first days of life. This means the true incidence could, in principle, be higher than the pooled estimate suggests, a possibility the authors acknowledge indirectly through their call for better data.

For clinicians and families, the practical message is clear. A 2.10 percent risk is low enough that most newborns with hemophilia will never experience a brain bleed, but high enough that every birth should be treated as an opportunity for prevention. When hemophilia is known or suspected before delivery, obstetric teams can choose the least traumatic route of birth, neonatologists can maintain a low threshold for cranial imaging, and hematologists can have replacement factor ready at the bedside. When there is no family history, the challenge is harder, but the growing availability of genetic carrier screening and heightened awareness among providers can shorten the path from first symptom to diagnosis and treatment. The study, published open access on October 6, 2026, and citable under DOI 10.1186/s12887-026-07750-1, adds a carefully quantified data point to a field that has long operated on fragmented numbers, and it makes a compelling case that the first twenty-eight days of life deserve far more systematic attention in the care of children with hemophilia.

Subject of Research: Neonatal intracranial hemorrhage risk in infants with hemophilia

Article Title: Risk of intracranial hemorrhage in neonates with hemophilia: a systematic review and meta-analysis

Article References: Zheng, M., Zheng, H., Li, Y., & Tu, J. (2026). Risk of intracranial hemorrhage in neonates with hemophilia: a systematic review and meta-analysis. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07750-1

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07750-1

Keywords: hemophilia, intracranial hemorrhage, neonatology, meta-analysis, systematic review, clotting factors, bleeding disorders, perinatal care, newborn screening, prophylaxis, BMC Pediatrics, birth trauma

The core of the argument is deceptively simple. A platelet count tells you how many platelets are circulating, but says nothing about whether they work. Platelets contribute to hemostasis through adhesion, activation, granule release, aggregation, and support of thrombin generation, and none of these functions is captured by a routine count. Multiple studies have now documented profound platelet dysfunction in patients with traumatic brain injury even when their counts sit comfortably within the normal range. The authors define this dysfunction as a measurable impairment in agonist-induced aggregation, in the responsiveness of specific receptor pathways, or in the platelet’s contribution to whole-blood clot strength, occurring disproportionately to or entirely in the absence of thrombocytopenia. In other words, a patient can have plenty of platelets and still have platelets that fail.

The biological explanation lies in the unique nature of brain injury. When neural tissue is disrupted, it releases tissue factor, damage-associated molecular patterns, microparticles, and lipid mediators into the circulation, triggering thrombin generation, platelet activation, and ultimately receptor desensitization. The result is a paradoxical hemostatic state the authors describe as activation exhaustion: early procoagulant activation coexists with downstream hyporesponsiveness. Platelet activation and platelet dysfunction, far from being mutually exclusive, appear to be overlapping temporal phases of the same post-injury response. This may explain a frustrating clinical pattern in which patients with traumatic brain injury suffer early hemorrhagic progression of their intracranial lesions and later develop thrombotic complications, two seemingly opposite outcomes arising from the same underlying biology.

The strongest mechanistic evidence comes from a study by Castellino and colleagues, who examined 70 patients with isolated head injury, carefully excluding hemorrhagic shock, hypotension, and antiplatelet medication use. In severe traumatic brain injury, they found adenosine diphosphate, or ADP, pathway inhibition of 93.1 percent, with an interquartile range of 44.8 to 98.3 percent, compared with just 15.5 percent in controls, a difference that was highly statistically significant, and the arachidonic acid pathway was involved concurrently. A parallel rat model confirmed ADP inhibition of 77.6 percent, plus or minus 6.7 percent, just 15 minutes after injury. These findings establish that brain injury alone, independent of systemic hemodynamic compromise, generates profound receptor-level platelet dysfunction, a mechanism distinct from pharmacological blockade and from inhibition driven by circulating mediators.

Current clinical guidelines recommend maintaining platelet counts above 50 billion per liter in active intracranial hemorrhage and above 100 billion per liter around surgery. Those thresholds remain essential, the authors stress, but they address only quantity. A patient whose count is well above both limits may still harbor significant dysfunction at the level of the ADP/P2Y12 or arachidonic acid/cyclooxygenase-1 receptor pathways. The authors also warn against two opposite errors: equating thrombocytopenia with platelet failure, and treating any detected dysfunction as an automatic indication for transfusion. Their framework rests on three clinical questions: which phenotype is present, is it clinically meaningful, and can correcting it actually improve outcomes?

Detecting these phenotypes requires functional testing, and here the landscape is complicated. Standard coagulation tests, including prothrombin time, international normalized ratio, and fibrinogen measurement, are essentially blind to platelet function. Viscoelastic assays such as thromboelastography and rotational thromboelastometry assess whole-blood clot kinetics and strength, and platelet mapping modules add agonist-specific response data. Other platforms, including Multiplate, VerifyNow, and light transmission aggregometry, measure different biological parameters and cannot be directly compared with one another. Cross-platform equivalence in traumatic brain injury has not been established, and the most frequently cited working thresholds, ADP or arachidonic acid inhibition greater than 60 percent on thromboelastography with platelet mapping, were never prospectively validated. They represent observational approximations, not clinical standards, and no universally accepted intervention cutoffs exist for any platform.

The therapeutic evidence is strikingly discordant, and the authors argue that the discordance follows a pattern rather than being random. On the positive side, one retrospective series found that goal-directed platelet transfusion guided by platelet mapping in severe traumatic brain injury was associated with lower mortality, and a platelet mapping algorithm reduced transfusion exposure without apparent harm in patients exposed to antiplatelet drugs. Against this, multiple studies found no benefit and potential harm from empirical platelet transfusion or desmopressin in less severely injured populations or when treatment was not guided by functional testing. The positive studies were conducted in severe injury with documented profound dysfunction and function-guided decisions; the negative studies applied empirical treatment in milder populations. The lesson, the authors conclude, is that intervention should be phenotype-guided and risk-stratified, not routine and empirical.

The risks of getting this wrong are not trivial. Platelet transfusion carries the danger of transfusion-associated circulatory overload, transfusion-related acute lung injury, alloimmunization, and prothrombotic complications, while desmopressin, typically dosed at 0.3 to 0.4 micrograms per kilogram intravenously in structured protocols, can cause hyponatremia, fluid retention, and thrombosis. The authors frame their recommendation through the lens of patient blood management: the question is not whether platelets are good or bad, but whether a clinically relevant, modifiable phenotype exists in which intervention is likely to change meaningful outcomes. They propose a five-category taxonomy matching platelet-related phenotypes to clinical context, dominant mechanism, and therapeutic implication, while candidly noting that this construct is expert-synthesized and has not been prospectively validated as a diagnostic classification system.

The practical approach they sketch is deliberately cautious. Platelet function testing is most defensible in moderate-to-severe injury, traumatic intracranial hemorrhage, radiological progression, planned neurosurgery or invasive neuromonitoring, known preinjury antiplatelet exposure, systemic polytrauma with coagulopathy, or unexplained bleeding despite a normal count. When function is preserved, empirical reversal should generally be avoided. When dysfunction is documented in high-risk patients requiring surgery or invasive monitoring, desmopressin or platelet transfusion may be considered according to phenotype, antiplatelet exposure, count, and procedural urgency, with post-intervention reassessment by clinical status, imaging, and repeat functional testing. Centers without access to viscoelastic platforms can fall back on clinical risk stratification using the Glasgow Coma Scale, lesion subtype, antiplatelet exposure, and procedural urgency, consistent with American College of Surgeons guidance. In emergent surgical scenarios, urgency simply overrides testing; in nonemergent settings, a 30-to-60-minute window permits targeted hemostatic preparation.

The authors are explicit about the limits of their case. Most clinical evidence is observational, retrospective, or single-center; interassay discordance remains a fundamental barrier; dysfunction rarely occurs in isolation and overlaps with fibrinogen abnormalities, acidosis, hypothermia, hypocalcemia, and hemodilution; the dynamic evolution of dysfunction over the first 72 hours is poorly characterized; and findings from moderate-to-severe cohorts cannot be extrapolated to mild injury. Many studies report laboratory correction without demonstrating improved patient outcomes. What they call for is a new generation of prospective, multicenter trials to determine which assay best identifies clinically meaningful dysfunction, which threshold predicts hemorrhagic progression, and whether phenotype-guided correction improves neurological outcomes rather than merely normalizing laboratory values. In neurocritical care, they write, what is hidden beyond the platelet count may be clinically decisive, and the next step is not simply to transfuse more platelets but to understand which platelet phenotype matters, when it matters, and how it can be safely corrected.

Subject of Research: Platelet dysfunction as a hemostatic phenotype in traumatic brain injury coagulopathy

Article Title: Rethinking Platelet Dysfunction in Traumatic Brain Injury: From Platelet Count to Hemostatic Phenotype

Article References: Quintana Diaz, M., & Godoy, D. A. (2026). Rethinking Platelet Dysfunction in Traumatic Brain Injury: From Platelet Count to Hemostatic Phenotype. Neurocritical Care. https://doi.org/10.1007/s12028-026-02670-5

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02670-5

Keywords: traumatic brain injury, platelet dysfunction, coagulopathy, hemostatic phenotype, thromboelastography, platelet mapping, platelet transfusion, desmopressin, intracranial hemorrhage, neurocritical care, patient blood management, P2Y12 pathway

The clinical scenario at the heart of the research is known as drip-and-ship. Most people who experience a large-vessel occlusion stroke, in which a major artery feeding the brain is blocked, arrive first at a primary stroke center, a community hospital equipped to diagnose stroke and administer thrombolytic drugs but not to perform endovascular thrombectomy, the catheter-based procedure that physically extracts the clot. Those patients must then be transferred to a comprehensive stroke center. During the transfer interval, which can span one to several hours, the blocked artery starves an ever-growing territory of brain tissue, and every minute of untreated ischemia destroys millions of neurons.

Whether to give thrombolysis before that transfer has been one of the most contested questions in stroke medicine. Intravenous thrombolysis uses drugs such as alteplase or tenecteplase to activate plasminogen and dissolve fibrin-rich clots, and it has long been standard care for eligible patients within four and a half hours of symptom onset. But after randomized trials such as DEVT, SKIP, DIRECT-SAFE, and MR CLEAN-NO IV suggested that thrombectomy alone might be sufficient for large-vessel occlusions, some physicians began questioning whether the added drug was worth the time, cost, and theoretical bleeding risk. Complicating matters, those trials mostly enrolled patients who were already at thrombectomy-capable centers, leaving the transfer population understudied.

Wang and colleagues set out to close that evidence gap. Following PRISMA 2020 reporting guidelines, they systematically searched PubMed, Embase, and ClinicalTrials.gov from database inception through July 2, 2026, identifying sixteen observational studies that compared intravenous thrombolysis with no thrombolysis before interhospital transfer in patients with large-vessel occlusion acute ischemic stroke. The primary efficacy outcome was excellent functional outcome, defined as a score of 0 to 1 on the modified Rankin Scale, a standard disability measure, at ninety days. Secondary outcomes included good functional outcome (modified Rankin Scale 0 to 2), arterial recanalization occurring during the interhospital interval, and poor outcome (scale scores of 5 to 6). Safety outcomes covered ninety-day mortality, symptomatic intracranial hemorrhage, hemorrhage of any kind, and parenchymal hematoma, a particularly damaging form of bleeding into the infarcted brain.

The results were striking. Pre-transfer thrombolysis was associated with a 72 percent higher odds of excellent functional outcome, with a pooled odds ratio of 1.72 and a 95 percent confidence interval of 1.47 to 2.01, a finding that reached the stringent threshold of p less than 0.00001. Good functional outcome showed a similar pattern, with an odds ratio of 1.64. Perhaps most remarkable was the effect on interhospital recanalization: patients who received the clot-dissolving drug before transfer were more than seven times as likely to have their blocked artery reopen before ever reaching the thrombectomy suite, with an odds ratio of 7.71. Spontaneous or drug-assisted reopening of the vessel during transport means that some patients arrive at the comprehensive center with blood flow already restored, potentially salvaging brain tissue that would otherwise have been lost.

The benefits extended to the worst outcomes as well. Patients treated with thrombolysis before transfer had 35 percent lower odds of ending up dead or fully dependent at ninety days, with an odds ratio of 0.65 for the composite poor outcome of modified Rankin Scale scores 5 to 6, and 31 percent lower odds of death, with an odds ratio of 0.69. Crucially, the safety signals showed no excess harm. The odds ratios for symptomatic intracranial hemorrhage (0.75), any intracranial hemorrhage (0.91), and parenchymal hematoma (1.43) all had confidence intervals crossing unity, indicating no statistically significant difference in bleeding risk between the treated and untreated groups.

Because observational studies are vulnerable to confounding, since sicker or atypical patients may be selected out of thrombolysis for legitimate clinical reasons, the researchers also performed adjusted analyses using the generic inverse variance method. These adjusted estimates confirmed the unadjusted picture. After accounting for measured differences between groups, pre-transfer thrombolysis remained significantly associated with excellent functional outcome (adjusted odds ratio 1.47), good functional outcome (adjusted odds ratio 1.61), interhospital recanalization (adjusted odds ratio 8.06), and reduced ninety-day mortality (adjusted odds ratio 0.64). The consistency of magnitude and direction across unadjusted and adjusted models strengthens the causal plausibility of the association, although randomized confirmation in the transfer population remains the gold standard.

The findings fit a coherent biological narrative that has emerged from earlier work. Studies of infarct core growth during transfer have shown that brain tissue continues to die during the interhospital interval, and that early recanalization dramatically slows this progression. Clinical prediction research on post-thrombolysis recanalization has demonstrated that a meaningful fraction of large-vessel occlusions reopen after thrombolytic administration, particularly in the hours following injection. A large individual participant data meta-analysis of six randomized trials published in the Lancet in 2023 similarly found that intravenous thrombolysis added value even when thrombectomy was performed. In the transfer setting specifically, recent work in Annals of Neurology and JAMA Neurology by Seners and colleagues has framed the interhospital interval as a promising therapeutic window in which thrombolysis can act while the clot remains otherwise untreated.

The practical implications are considerable for the geography of stroke care. Thrombectomy is a resource-intensive procedure requiring a neurointerventionalist, a biplane angiography suite, and round-the-clock anesthesia and neurocritical care support, and global access studies have shown that most of the world’s population lives far from a center capable of performing it. In hub-and-spoke telestroke networks, drip-and-ship remains the dominant model for reaching these patients. The new analysis suggests that in resource-limited settings where timely thrombectomy is simply not immediately accessible, administering thrombolysis at the primary stroke center before dispatching the ambulance is an effective reperfusion strategy that buys real, measurable benefit during transport. Some single-center studies have even suggested that spoke-administered thrombolysis shortens subsequent procedure time and reduces the number of device passes needed, likely because partially dissolved clots are easier to extract.

Several caveats temper the conclusions. All sixteen included studies were observational, so residual confounding by indication cannot be excluded, and the ongoing debate over thrombectomy with or without intravenous thrombolysis, including the recent tenecteplase-before-thrombectomy trial published in the New England Journal of Medicine, shows that the field is still actively evolving. Heterogeneity across studies in drug choice, timing, imaging selection, and transfer distance may also influence the pooled estimates. Nonetheless, by synthesizing the full evidence base specific to the transfer population, the meta-analysis provides the most precise answer to date. For the physicians deciding whether to start the infusion at a community hospital at two in the morning before loading a stroke patient into an ambulance, the message is now substantially clearer: the drug given before the wheels start turning appears to reopen vessels, save brain, and save lives, and it does so without adding hemorrhagic danger.

Subject of Research: Intravenous thrombolysis before interhospital transfer for endovascular thrombectomy in large-vessel occlusion stroke

Article Title: Intravenous thrombolysis use before interhospital transfer for thrombectomy: a systematic review and meta-analysis

Article References: Wang, Z., Chen, Y., Li, J., Yuan, B., Wang, W., Li, J., & Ma, Q. (2026). Intravenous thrombolysis use before interhospital transfer for thrombectomy: a systematic review and meta-analysis. Journal of Neurology, 273(10), Article 630. https://doi.org/10.1007/s00415-026-14173-6

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14173-6

Keywords: ischemic stroke, thrombolysis, thrombectomy, interhospital transfer, large-vessel occlusion, drip-and-ship, meta-analysis, recanalization, intracranial hemorrhage, stroke outcomes, tenecteplase, stroke centers

The new guideline represents a substantial methodological step forward. Where the 2016 document relied on more traditional evidence appraisal, the update applies stringent Grading of Recommendations Assessment, Development, and Evaluation criteria, the current international standard for evaluating the certainty of medical evidence. The authors also performed formal meta-analyses, pooling data across studies to generate more precise estimates of benefit and harm. Five specific questions, framed in the PICO format of population, intervention, comparison, and outcome, structured the effort: whether andexanet alfa outperforms prothrombin complex concentrates for reversing direct factor Xa inhibitors; whether desmopressin helps patients on antiplatelet drugs; whether platelet transfusion improves outcomes; whether coagulopathy reversal benefits patients with very small hemorrhages; and whether viscoelastic hemostatic testing, such as thromboelastography and rotational thromboelastometry, meaningfully improves mortality, functional recovery, thrombosis rates, hemorrhage expansion, or treatment-related adverse events. Recommendations were further stratified by whether the bleeding was spontaneous or traumatic, an important distinction that reflects growing recognition that these two patient populations behave differently.

Notably, the update deliberately left many of the 2016 recommendations untouched. Reversal strategies for vitamin K antagonists such as warfarin, direct thrombin inhibitors, unfractionated heparin, low molecular weight heparin, pentasaccharides, and thrombolytics were not re-reviewed, largely because no compelling new literature had emerged that would substantively alter the prior guidance. That decision itself carries information: a decade of research has reshaped thinking in some corners of antithrombotic reversal while leaving others remarkably stable. The most dramatic shifts concern the factor Xa inhibitor antagonists, the class of oral anticoagulants that includes apixaban and rivaroxaban and that has steadily displaced warfarin in clinical practice.

The spotlight falls squarely on andexanet alfa, a recombinant decoy protein engineered to bind factor Xa inhibitors in the bloodstream and neutralize their anticoagulant effect. Early enthusiasm was fueled by the ANNEXA-4 study, which demonstrated that andexanet effectively reduced expansion of intraparenchymal hematomas. Yet adoption was hampered from the outset by the drug’s extraordinarily high cost, and Frontera’s own prior work quantified just how stark the price gap is compared with prothrombin complex concentrates, the four-factor blood products that have long served as the workhorse reversal agent. The pivotal test arrived with ANNEXA-I, a randomized trial that pitted andexanet against usual care, with 86 percent of the comparator group receiving prothrombin complex concentrates. Andexanet achieved significantly better hemostatic efficacy, but that win came with a sobering price: a 5 percent absolute increase in thrombotic events within 30 days, driven particularly by ischemic strokes. Mortality and functional outcomes showed no difference between the arms, leaving clinicians facing an uncomfortable question about which harm matters more, ongoing hematoma expansion or a treatment-emergent ischemic stroke.

The new guideline’s meta-analyses sharpened that trade-off into hard numbers. Pooling the available data suggested a modest but statistically significant 9 percent relative improvement in hemostatic efficacy for andexanet over prothrombin complex concentrates. Against that benefit stood a significant 35 percent relative increase in thrombotic events. Further meta-analyses found no mortality or functional outcome advantage for andexanet, and, perhaps most strikingly for health systems, both hospital and intensive care unit lengths of stay were longer when andexanet was used. The pharmacology helps explain the thrombosis signal: andexanet does not simply remove apixaban or rivaroxaban from the body, it floods the circulation with inert decoys that also bind endogenous tissue factor pathway inhibitor, transiently unleashing coagulation beyond the point of simple reversal. Weighing all of this, the Neurocritical Care Society recommendation now diverges sharply from its European counterpart, the European Stroke Organisation and the European Association of Neurosurgical Societies, whose expert consensus still suggests considering andexanet in adults with spontaneous intracranial hemorrhage on factor Xa inhibitors who present within 15 hours of their last dose, or with proven anti-factor Xa activity above 100 nanograms per milliliter, and within 12 hours of symptom onset. Frontera notes that the European position rests primarily on the ANNEXA-I trial alone, whereas the North American guideline synthesized multiple meta-analyses. The situation is further complicated by market reality: andexanet is no longer available in the United States as of December 2025, though it remains accessible elsewhere in the world, meaning that international practitioners must still navigate these conflicting recommendations at the bedside.

A second provocative question addressed by the guideline is whether anticoagulation reversal should be abandoned for very small hemorrhages, defined here as an intraparenchymal hematoma volume of 10 milliliters or less. The intuition seems reasonable: if a bleed is tiny, perhaps the risks of procoagulant reversal, including thrombosis, outweigh any benefit. But the trial data undercut that logic in an unexpected way. The median hematoma volume in ANNEXA-I was only 10 milliliters, and just 13 milliliters in the earlier INCH trial of vitamin K antagonist reversal. Both studies demonstrated improvements in laboratory measures of coagulopathy and reductions in hematoma expansion, suggesting that even small hemorrhages benefit from reversal. Paradoxically, the data gap lies at the other end of the spectrum: patients with very large hemorrhages were typically excluded from randomized trials, so clinicians managing the sickest patients have the least rigorous evidence to guide them.

The biology of hemorrhage location adds another layer of nuance. The same volume of blood wreaks very different degrees of damage depending on where it accumulates in the brain. A recent analysis cited in the commentary identified volume thresholds that predict poor 90-day outcomes, defined as modified Rankin scores of 4 through 6, and found that the critical threshold is substantially lower for deep hemorrhages, at 17 milliliters or more, than for lobar hemorrhages, at 36 milliliters or more. A deep bleed near critical structures such as the brainstem can be catastrophic at volumes that would be survivable in a lobar location. In other words, even modest expansion of a small deep hemorrhage could translate into substantially worse functional outcomes, which strengthens the argument that initial volume alone should not determine whether reversal is offered. Timing matters too: the time from last known well and the time since the last antithrombotic dose are key predictors of expansion, as are imaging biomarkers such as the spot sign on contrast-enhanced CT, which identifies active extravasation.

The temporal dynamics of risk provide perhaps the most persuasive clinical argument in the commentary. Within the first 48 hours after an intracerebral hemorrhage begins, the risk of hematoma expansion dwarfs the thromboembolic risk of temporarily stopping antithrombotic therapy. The danger of ischemic events off anticoagulation rises only in a delayed fashion, after several days. Even patients at extremely high thromboembolic risk, including those with mechanical heart valves and left ventricular assist devices, appear to tolerate anticoagulation reversal well, with low thromboembolic rates during the first 7 to 14 days after hemorrhage onset. Given that these are the very patients for whom clinicians most fear withholding anticoagulation, the evidence suggests the acute reversal decision can be made with relative confidence. Although the guideline authors judged the data insufficient to issue a formal recommendation on reversal for small-volume hemorrhages, Frontera argues that offering reversal in the acute window, when expansion risk peaks, is prudent regardless of initial volume or the original indication for anticoagulation.

The final significant shift concerns desmopressin, commonly known as DDAVP, a vasopressin analog that increases circulating levels of von Willebrand factor and factor VIII and has been proposed as a hemostatic agent for patients bleeding while on antiplatelet drugs such as aspirin and clopidogrel. The 2016 guideline had conditionally recommended DDAVP on the basis of low-quality evidence. Applying rigorous GRADE criteria to the accumulated data, the new meta-analyses found no significant benefit for hematoma expansion, mortality, functional outcome, or length of stay, and the guideline therefore makes no recommendation either for or against the drug. Importantly, serious adverse events were similar with and without desmopressin, both in the pooled analyses and in the DASH trial, a randomized, placebo-controlled feasibility study from the United Kingdom that established the safety foundation for a definitive phase III investigation. Both the North American and European guidelines urge enrollment of eligible patients in trials testing desmopressin’s utility, though no such phase III study is currently open. In the interim, Frontera observes that the trend toward less expansion, the demonstrated safety record, the low cost, the mechanistic plausibility, and the absence of alternative hemostatic options for antiplatelet-associated bleeding may reasonably lead practitioners to prescribe it anyway, a rare instance of a guideline update explicitly acknowledging the gap between evidence and bedside reality. The broader message is clear: for traumatic brain injury-related hemorrhage and for hemostatic agents in antiplatelet bleeding, the field still needs well-designed trials before certainty can replace consensus.

Subject of Research: Emergency reversal of antithrombotic therapy in adult intracranial hemorrhage per a 2026 neurocritical care guideline update

Article Title: Commentary on: Treatment of Antithrombotic-Associated Intracranial Hemorrhage in Adults: A Focused Guideline Update from the Neurocritical Care Society and Society of Critical Care Medicine

Article References: Commentary on: Treatment of Antithrombotic-Associated Intracranial Hemorrhage in Adults: A Focused Guideline Update from the Neurocritical Care Society and Society of Critical Care Medicine. (n.d.). https://doi.org/10.1007/s12028-026-02639-4

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02639-4

Keywords: intracranial hemorrhage, anticoagulation reversal, andexanet alfa, prothrombin complex concentrate, desmopressin, factor Xa inhibitors, hematoma expansion, Neurocritical Care Society, GRADE methodology, antiplatelet therapy, thromboembolism, viscoelastic testing

The stakes of this question are enormous. Antithrombotic drugs, including anticoagulants and antiplatelet agents, are prescribed to millions of people for atrial fibrillation, venous thromboembolism, and cardiovascular disease, and they dramatically increase the risk and severity of intracranial hemorrhage. Compared with patients who bleed while not taking these medications, those on antithrombotics face higher rates of hematoma expansion, worse functional outcomes, and greater mortality. Hematoma expansion is the central villain in this story: every additional milliliter of blood within the brain parenchyma carries roughly a five percent increased risk of death or dependency, and approximately a third of patients who present within six hours of symptom onset will experience significant growth of their hemorrhage. Rapid reversal of anticoagulation is therefore one of the most consequential decisions in emergency neurology.

The guideline panel, an interdisciplinary task force of ten specialists spanning neurocritical care, trauma surgery, hematology, nursing, and pharmacy, framed five clinical questions using the Population, Intervention, Comparator, Outcome framework. Three questions updated prior recommendations while two were entirely new. The panelists independently rated outcomes by importance, elevating mortality, functional outcome, and thrombosis to critical status, and applied the Grading of Recommendations, Assessment, Development, and Evaluation methodology to synthesize evidence from randomized trials and observational cohorts. Notably, the panel included a public member recruited through the Anticoagulation Forum to represent the patient and family perspective, and all members were vetted for conflicts of interest before voting.

The most consequential recommendation concerns the showdown between andexanet alfa and prothrombin complex concentrate. Andexanet alfa is an inactive recombinant decoy form of human factor Xa that sponges up factor Xa inhibitors and restores thrombin generation. It was not commercially available when the 2016 guideline was written, and its subsequent rise was propelled largely by the ANNEXA-4 trial, a single-arm study of 352 patients in which 82 percent achieved excellent or good hemostasis. But the new analysis, drawing on 21 studies encompassing 4,938 patients, tells a more sobering story. The sole randomized trial, ANNEXA-I, compared andexanet alfa against usual care in factor Xa inhibitor-associated intracerebral hemorrhage and found no significant mortality benefit: 27.8 percent of andexanet recipients died versus 25.5 percent of those receiving usual care. Andexanet did improve hemostatic efficacy, with 67 percent achieving the composite hemostasis endpoint compared with 53.1 percent under usual care, and it produced less very large hematoma expansion. Yet hemostasis is a surrogate outcome, and the panel prioritized patient-centered endpoints instead.

What tipped the scales decisively was thrombosis. Meta-analysis revealed a significant increase in thrombotic events with andexanet alfa, with a relative risk of 1.37 overall, and in the spontaneous hemorrhage subgroup the risk nearly doubled at a relative risk of 1.99. These events were predominantly arterial, most commonly acute ischemic strokes identified on neuroimaging, and even small asymptomatic infarcts may erode long-term functional recovery. Andexanet alfa appears prothrombotic through two distinct mechanisms: reversal of anticoagulation itself, and direct inhibition of tissue factor pathway inhibitor. These findings contributed to the United States Food and Drug Administration declining AstraZeneca’s application for full approval, and the manufacturer voluntarily withdrew the drug from the US market as of December 2025, though it remains available internationally. The panel therefore issued a conditional recommendation favoring four-factor prothrombin complex concentrate over andexanet alfa for both spontaneous and traumatic factor Xa inhibitor-associated hemorrhage, the latter based on very low certainty evidence.

The guideline also delivers a nuanced verdict on platelet transfusion, long a reflexive response to bleeding on antiplatelet drugs like aspirin and clopidogrel. For patients with spontaneous intraparenchymal hemorrhage who do not require surgery, the panel recommends against platelet transfusion, a position anchored by the PATCH trial, a high-quality randomized study showing that transfusion offered no benefit in mortality, functional outcome, or thrombosis, and in fact was associated with worse functional outcomes. The picture flips for surgical patients: a single randomized trial from China found that aspirin users undergoing craniotomy for basal ganglia hemorrhage who received perioperative platelet transfusion had lower mortality, reduced postoperative hemorrhage, and better six-month functional outcomes. The panel accordingly suggests platelet transfusion for aspirin-treated patients requiring neurosurgery, while explicitly limiting this recommendation to aspirin because no data exist for P2Y12 inhibitors in this setting. For traumatic intracranial hemorrhage, where ten retrospective studies produced contradictory and confounded results, the panel declined to make any recommendation at all.

Desmopressin, a vasopressin analog that releases factor VIII and von Willebrand factor and may enhance platelet procoagulant activity, fared no better. The 2016 guideline had suggested considering a single dose for antiplatelet-associated hemorrhage, but the new analysis, including the DASH phase 2 feasibility trial and nine observational studies, found no effect on hematoma expansion, mortality, or functional outcome, with all confidence intervals crossing unity. The panel made no recommendation, while emphasizing the urgent need for adequately powered randomized trials of a treatment that remains biologically plausible for a condition with no proven therapy. Similarly, the panel could not issue guidance on whether to reverse anticoagulation in patients with very small intraparenchymal hemorrhages, a genuinely difficult clinical dilemma, since no studies directly address it. The decision hinges on factors such as time from onset to imaging, hemorrhage location, the specific anticoagulant and timing of the last dose, and imaging markers like the CT spot sign that predict expansion.

One genuinely new recommendation embraces technology over therapeutics. Viscoelastic hemostatic assays, including thromboelastography and rotational thromboelastometry, are point-of-care whole blood tests that render real-time coagulation dynamics rather than static snapshots. The panel suggests using these assays to guide treatment of coagulopathy in traumatic intracranial hemorrhage when available, a conditional recommendation resting on very low certainty evidence but supported by a mortality signal in the severe traumatic brain injury subgroup of one randomized trial, with a relative risk of 0.59. Because the tests carry minimal inherent risk compared with medications or transfusions, the panel judged the balance favorable even with sparse data, though it acknowledged that treatment protocols vary widely between centers and that standardized algorithms remain lacking.

The panel was candid about the limitations pervading this literature. Observational studies comparing andexanet with prothrombin complex concentrate are vulnerable to selection bias, since patients assigned to usual care were often treated later, had higher blood pressures, or were perceived as having better prognoses, patterns that could artificially favor andexanet. Formulations of prothrombin complex concentrate differ in factor content, some contain heparin, and none carries a labeled indication for factor Xa inhibitor reversal, while optimal dosing, historically 50 units per kilogram, was never established on robust data. The panel also advised against combining andexanet alfa with prothrombin complex concentrate unless benefit clearly outweighs the prothrombotic risk, and flagged a practical pitfall: patients transferred between hospitals may arrive without documentation of reversal agents already given.

Perhaps the most telling conclusion is what the guideline could not say. Not a single strong recommendation emerged from the entire exercise, a reflection of how thin the evidence remains for one of the most feared complications of modern cardiovascular medicine. The panel laid out a research agenda calling for randomized trials of platelet transfusion in traumatic hemorrhage, adequately powered studies of desmopressin, direct comparisons of reversal versus observation in small hemorrhages, and standardized viscoelastic assay protocols. Until those trials arrive, clinicians now have a clearer, more skeptical map of the territory: favor prothrombin complex concentrate over andexanet, withhold platelets from non-surgical patients, give them to aspirin users heading for the operating room, and let real-time coagulation testing steer trauma resuscitation. In a field where overtreatment has proven as dangerous as undertreatment, knowing what not to do may be the guideline’s most valuable contribution.

Subject of Research: Guideline-based reversal of antithrombotic medications in adults with acute intracranial hemorrhage

Article Title: Treatment of Antithrombotic-Associated Intracranial Hemorrhage in Adults: A Focused Guideline Update from the Neurocritical Care Society and the Society of Critical Care Medicine

Article References: Vallejo, M. C., Kennedy, L. S., Dengler, B., Barthol, C., Belley-Cote, E. P., Burns, J. D., Chau, V. K., Cordonnier, C., Cuker, A., Honarmand, K., Mahmoud, S. H., Wilcox, M. E., & Kumar, M. A. (2026). Treatment of Antithrombotic-Associated Intracranial Hemorrhage in Adults: A Focused Guideline Update from the Neurocritical Care Society and the Society of Critical Care Medicine. Neurocritical Care. https://doi.org/10.1007/s12028-026-02601-4

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02601-4

Keywords: intracranial hemorrhage, antithrombotic reversal, andexanet alfa, prothrombin complex concentrate, platelet transfusion, desmopressin, factor Xa inhibitors, antiplatelet agents, viscoelastic hemostatic assays, GRADE methodology, neurocritical care, clinical guideline